Skip to main content

 Scientific publications

Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial.

Authors : Abi Jaoude J, de Azambuja E, Makki M, Tamim H, Tfayli A, Geara F, Piccart M, Poortmans P, Zeidan YH
Year : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 106
Pages : 503-510

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.

Authors : de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber Rd, Piccart-Gebhart M, Suter T
Year : 2020
Journal : Breast Cancer Res Treat
Volume : 179
Pages : 161-171

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Authors : Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K
Year : 2020
Journal : Ann Oncol
Volume : 31
Pages : 171-190

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.

Authors : Pondé N, Amaye L, Lambertini M, Paesmans M, Piccart M, de Azambuja E
Year : 2020
Journal : Eur J Cancer
Volume : 126
Pages : 65-73

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tria

Authors : Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E
Year : 2019
Journal : Lancet Oncol
Volume : 20
Pages : 1226-1238

Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.

Authors : Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Lang I, Smith I, Boyle F, Xu B, Lecocq C, Wildiers H, Jouannaud C, Hackman J, Dasappa L, Ciruelos E, Toral Pena JC, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber Rd, Piccart-Gebhart M, Di Cosimo S
Year : 2019
Journal : Eur J Cancer
Volume : 118
Pages : 169-177

PERSEPHONE - implications for clinical practice in 2019.

Authors : Pondé N, de Azambuja E
Year : 2019
Journal : Nat Rev Clin Oncol
Volume : 16
Pages : 663-664

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

Authors : Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber Rd
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1507-1513

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors : Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber Rd, Piccart-Gebhart M, Mobus V, de Azambuja E
Year : 2019
Journal : Clin Breast Cancer

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.

Authors : Brandão M, Caparica R, Eiger D, de Azambuja E
Year : 2019
Journal : Ann Oncol
Volume : 30 Suppl 10
Pages : x27-x42

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.

Authors : Brandão M, Caparica R, Eiger D, de Azambuja E
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : x27-x42

Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial.

Authors : Lambertini M, Poggio F, Bruzzone M, Conte B, Bighin C, de Azambuja E, Giuliano M, De Laurentiis M, Cognetti F, Fabi A, Bisagni G, Durando A, Turletti A, Urracci Y, Garrone O, Puglisi F, Montemurro F, Ceppi M, Del Mastro L
Year : 2019
Journal : Int J Cancer

Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.

Authors : Sonnenblick A, Bailey A, Uziely B, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Cameron D, Bell R, Zardavas D, Al-Sakaff N, Gelber Rd, Dowsett M, Leyland-Jones B, Piccart-Gebhart M, de Azambuja E
Year : 2019
Journal : Anticancer Res
Volume : 39
Pages : 797-802

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Authors : Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber Rd, Coates AS, Goldhirsch A, Thürlimann B, Regan MM
Year : 2019
Journal : J Clin Oncol
Volume : 37
Pages : 105-114

Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.

Authors : Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M
Year : 2019
Journal : Breast Cancer Res Treat
Volume : 174
Pages : 27-37

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.

Authors : Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, De Braud FG, Apolone G, Verderio P, Tagliabue E
Year : 2019
Journal : Eur J Cancer
Volume : 118
Pages : 1-9

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

Authors : Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber Rd
Year : 2019
Journal : Ann Oncol
Volume : 30
Pages : 1507-1513

How I treat metastatic triple-negative breast cancer.

Authors : Caparica R, Lambertini M, de Azambuja E
Year : 2019
Journal : ESMO Open
Volume : 4
Pages : e000504

Targeted therapy for breast cancer in older patients.

Authors : Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Lago LD
Year : 2019
Journal : J Geriatr Oncol

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Authors : Lambertini M, Campbell C, Gelber Rd, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E
Year : 2019
Journal : Breast Cancer Res Treat
Volume : 177
Pages : 103-114